Multivariate evaluation of pharmacological responses in early clinical trials - A study of rIL-21 in the treatment of patients with metastatic melanoma

British Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2010, Pages 379-390

  Rasmussen, Morten Arendt ^a   Colding Jørgensen, Morten ^b   Hansen, Lasse Tengbjerg ^b   Bro, Rasmus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Chemometrics; IL 21; Malignant melanoma; Multivariate; Orthogonalization; PCA; Principal components

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD56 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PERFORIN; RECOMBINANT CYTOKINE; RECOMBINANT HUMAN INTERLEUKIN 21; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; CANCER CENTER; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; MEAN CORPUSCULAR HEMOGLOBIN; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; MELANOMA; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 77949407794     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03600.x     Document Type: Article

References (19)

1. Wold S, Esbensen K, Geladi P. Principal component analysis. Chemometr Intell Lab 1987; 2: 37-52.
2. Christie OHJ. Introduction to multivariate methodology. An alternative way? Chemometr Intell Lab 1995; 29: 177-88.
3. Tarassenko L, Hann A, Young D. Integrated monitoring and analysis for early warning of patient deterioration. Br J Anaesth 2006; 97: 64-8.
4. Albanese J, Martens K, Karkanitsa LV, Dainiak N. Multivariate analysis of low-dose radiation-associated changes in cytokine gene expression profiles using microarray technology. Exp Hematol 2007; 35: 47-54.
5. Liszka-Hackzell JJ, Schött U. Presentation of laboratory and sonoclot variables using principal component analysis: identification of hypo- and hypercoagulation in the HELLP syndrome. J Clin Monit Comput 2004; 18: 247-52.
6. Keun HC. Metabonomic modeling of drug toxicity. Pharmacol Ther 2006; 109: 92-106.
7. Keun HC, Athersuch TJ. Application of Metabonomics in drug development. Pharmacogenomics 2007; 8: 731-41.
8. Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008; 123: 575-83.
9. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NPH, Skak K, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007; 13: 3630-6.
10. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PEG, McAthur GA. Clinical and biological efficacy of recombinant human interleukin-21 (rIL-21) in patients with stage 4 malignant melanoma without prior treatment: a phase 2a trial. Clin Cancer Res 2009; 15: 2123-9.
11. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008; 26: 2034-9.
12. + T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008; 57: 1439-49.
13. Krijnen WP, Kiers HAL. An efficient algorithm for weighted PCA. Comput Stat 1995; 10: 299-306.
14. Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD. Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol Immunother 2009; 58: 843-54.
15. Box EP, Hunter WG, Hunter JS. Statistics for Experimenters. New York: John Wiley and Sons, 1978.
16. Jackson JE. Principal components and factor analysis: part I - principal components. J Qual Technol 1980; 12: 201-13.
17. Bro R, Kjeldahl K, Smilde AK, Kiers HAL. Cross-validation of component models: a critical look at current methods. Anal Bioanal Chem 2008; 390: 1241-51.
18. Ledauphin S, Hanafi M, Qannari EM. Simplification and signification of principal components. Chemometrics Int Laboratory Systems 2004; 74: 277-81.
19. Bro R, Smilde AK. Centering and scaling in component analysis. J Chemometrics 2003; 17: 16-33.